Bupropion: pharmacology and therapeutic applications (Q34569990)

3 August 2017

1 reference

title

Bupropion: pharmacology and therapeutic applications (English)

1 reference

3 August 2017

1 reference

Kevin F Foley

1

1 reference

PubMed ID

17009913

3 August 2017

Kevin P DeSanty

series ordinal

2

1 reference

PubMed ID

17009913

3 August 2017

Richard E Kast

series ordinal

3

1 reference

3 August 2017

1 September 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

1249-1265

1 reference

3 August 2017

9

1 reference

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion overdose: a 3-year multi-center retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Convulsant and anticonvulsant effects of bupropion in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Safety profile of sustained-release bupropion in depression: results of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Binding of antidepressants to human brain receptors: focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

The relationship between antidepressant medication use and rate of suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Adverse effects associated with extra doses of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Intentional bupropion overdoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Intraventricular conduction delay after bupropion overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion exposures: clinical manifestations and medical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Inhibition of CYP2D6 activity by bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Nortriptyline toxicity secondary to interaction with bupropion sustained-release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Sertraline-phenelzine drug interaction: a serotonin syndrome reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Fatal interaction between tranylcypromine and imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Pharmacological therapies for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Behavioral and biochemical investigations of bupropion metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion increases striatal vesicular monoamine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Apomorphine-induced penile erections in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Lithium ions modulate the expression of VMAT2 in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

How does bupropion work as a smoking cessation aid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Plasma nortriptyline and clinical response in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Placebo response in studies of major depression: variable, substantial, and growing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Combined antidepressants: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion SR for the treatment of postpartum depression: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion for smoking cessation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Effect of bupropion on depression symptoms in a smoking cessation clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion in the management of apathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion may improve restless legs syndrome: a report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Antidepressants and periodic leg movements of sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Bupropion and chronic aphthous ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Remission of Crohn's disease on bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Crohn’s disease remission on bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1249

10.1586/14737175.6.9.1249

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

17009913